Repare Therapeutics, Inc.
Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Repare Therapeutics, Inc. |
Ticker: | Ticker: RPTX |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). The investigation concerns whether Repare and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On January 25, 2024, Repare revealed a $40 million milestone payment from its collaboration with Roche for the development and commercialization of camonsertib, an ATR inhibitor. On February 12, 2024, Repare issued a press release “announc[ing] . . . that it will regain global development and commercialization rights to camonsertib…following termination of its collaboration agreement with Roche.” According to the press release, “Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.” On this news, the price of Repare shares declined by $1.31 per share, or approximately 15.58%, from $8.41 per share on February 12, 2024 to close at $7.10 on February 13, 2024.
On January 25, 2024, Repare revealed a $40 million milestone payment from its collaboration with Roche for the development and commercialization of camonsertib, an ATR inhibitor. On February 12, 2024, Repare issued a press release “announc[ing] . . . that it will regain global development and commercialization rights to camonsertib…following termination of its collaboration agreement with Roche.” According to the press release, “Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.” On this news, the price of Repare shares declined by $1.31 per share, or approximately 15.58%, from $8.41 per share on February 12, 2024 to close at $7.10 on February 13, 2024.